To assess the feasibility and tolerance of neoadjuvant and concomitant estramustine phosphate and vinblastine (EV) with high-dose three-dimensional conformal radiotherapy (3D-CRT) for patients with unfavorable-risk prostate cancer.
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Department of Radiation Oncology, Solid Tumor Service, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. zelefskm@mskcc.org
